Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIVELLA vs AEROSEB-HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
FDA-approved for the treatment of eczematous dermatitis, atopic dermatitis, and other glucocorticoid-responsive dermatoses complicated by fungal or bacterial infections
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
1.5-2 hours (terminal) after intravenous administration; prolonged in hepatic impairment.
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Hydrocortisone is primarily hepatic via CYP3A4; iodoquinol is not extensively metabolized, with partial glucuronidation and enterohepatic circulation.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Renal (primarily as metabolites; <5% unchanged); fecal (biliary excretion of metabolites).
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
90-95% (albumin and corticosteroid-binding globulin).
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
0.4-0.6 L/kg; indicates distribution into total body water and tissues.
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
Oral: 80-90%; Intramuscular: 100%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
No adjustment required for topical application. Systemic absorption is minimal; however, in severe renal impairment (GFR <30 m L/min), use caution due to potential systemic corticosteroid effects.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
No specific adjustment for topical use. In Child-Pugh C cirrhosis, consider the risk of systemic corticosteroid accumulation; use with caution.
Not indicated for use in pediatric patients; safety and efficacy not established.
Children >2 years: Apply a thin film to affected area twice daily for up to 7 days. Avoid prolonged use, occlusion, or application to large body surface areas. Safety in children <2 years not established.
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
Elderly patients: Use the lowest effective duration and avoid prolonged use due to increased risk of skin atrophy and systemic absorption. Apply sparingly to limited areas.
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
None
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
Prolonged use may lead to systemic corticosteroid effects, including HPA axis suppression, Cushing's syndrome, and hyperglycemia.,Risk of secondary infection due to immunosuppression.,Local adverse reactions such as skin atrophy, striae, and perioral dermatitis.,Avoid use in diaper area or under occlusive dressings.
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
Hypersensitivity to any component (hydrocortisone, iodoquinol, or sulfites).,Viral or fungal infections without appropriate antimicrobial coverage.,Immunocompromised patients (systemic use relative).,Pregnancy (category C, use only if benefit outweighs risk).
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
No clinically significant food interactions are reported for topical hydrocortisone/pramoxine. No dietary restrictions necessary.
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
FDA Pregnancy Category C. First trimester: limited data, no increased risk of major malformations identified in small studies. Second and third trimesters: potential for fetal adrenal suppression with prolonged use; avoid high doses and prolonged exposure.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
Present in breast milk in low concentrations. M/P ratio not determined. Use with caution, especially with high doses or prolonged treatment; risk of infant adrenal suppression theoretical.
Not applicable; contraindicated in pregnancy.
No standard dose adjustments required for pregnancy-related pharmacokinetic changes. Use lowest effective dose for shortest duration. Avoid high-dose or prolonged use in pregnancy.
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
AEROSEB-HC is a combination aerosol foam containing hydrocortisone acetate 1% and pramoxine hydrochloride 1% for topical use. It is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly in anogenital areas. The foam formulation enhances penetration and is less messy than ointments. Advise patients to avoid contact with eyes and mucous membranes. Use with caution in patients with skin infections or atrophy. Prolonged use in intertriginous areas may increase risk of local and systemic adverse effects.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
Apply a small amount to the affected area as directed, usually 2-4 times daily.,Do not cover the area with bandages or dressings unless instructed by your doctor.,Avoid use on broken skin, open wounds, or infected areas unless specifically prescribed.,Do not use for more than 2 weeks without medical supervision, especially in the anogenital region.,If symptoms do not improve or worsen, contact your healthcare provider.,Keep away from eyes, mouth, and other mucous membranes.,Wash hands after applying unless treating hands.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIVELLA vs AEROSEB-HC, answered by our medical review team.
ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. AEROSEB-HC is a Topical Corticosteroid that works by AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIVELLA and AEROSEB-HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. The standard adult dose of AEROSEB-HC is: AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIVELLA and AEROSEB-HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. AEROSEB-HC is classified as Category C. FDA Pregnancy Category C. First trimester: limited data, no increased risk of major malformations identified in small studies. Second and third trimesters: potential for fetal adre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.